ENTX vs. ATRA, CVM, TARA, TIL, TSBX, CGTX, IKNA, DTIL, ELUT, and JATT
Should you be buying Entera Bio stock or one of its competitors? The main competitors of Entera Bio include Atara Biotherapeutics (ATRA), CEL-SCI (CVM), Protara Therapeutics (TARA), Instil Bio (TIL), Turnstone Biologics (TSBX), Cognition Therapeutics (CGTX), Ikena Oncology (IKNA), Precision BioSciences (DTIL), Elutia (ELUT), and JATT Acquisition (JATT). These companies are all part of the "biological products, except diagnostic" industry.
Atara Biotherapeutics (NASDAQ:ATRA) and Entera Bio (NASDAQ:ENTX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, earnings, valuation, community ranking, profitability, risk and dividends.
Atara Biotherapeutics has a beta of 0.7, indicating that its share price is 30% less volatile than the S&P 500. Comparatively, Entera Bio has a beta of 1.63, indicating that its share price is 63% more volatile than the S&P 500.
Entera Bio has a net margin of 0.00% compared to Entera Bio's net margin of -671.70%. Atara Biotherapeutics' return on equity of -103.40% beat Entera Bio's return on equity.
70.9% of Atara Biotherapeutics shares are held by institutional investors. Comparatively, 14.1% of Entera Bio shares are held by institutional investors. 4.5% of Atara Biotherapeutics shares are held by company insiders. Comparatively, 8.9% of Entera Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Entera Bio has lower revenue, but higher earnings than Atara Biotherapeutics. Entera Bio is trading at a lower price-to-earnings ratio than Atara Biotherapeutics, indicating that it is currently the more affordable of the two stocks.
Atara Biotherapeutics received 255 more outperform votes than Entera Bio when rated by MarketBeat users. Likewise, 67.67% of users gave Atara Biotherapeutics an outperform vote while only 66.92% of users gave Entera Bio an outperform vote.
Atara Biotherapeutics currently has a consensus target price of $28.00, suggesting a potential upside of 4,538.83%. Entera Bio has a consensus target price of $10.00, suggesting a potential upside of 284.62%. Given Entera Bio's higher possible upside, equities analysts plainly believe Atara Biotherapeutics is more favorable than Entera Bio.
In the previous week, Entera Bio had 12 more articles in the media than Atara Biotherapeutics. MarketBeat recorded 17 mentions for Entera Bio and 5 mentions for Atara Biotherapeutics. Entera Bio's average media sentiment score of 0.95 beat Atara Biotherapeutics' score of 0.44 indicating that Atara Biotherapeutics is being referred to more favorably in the media.
Summary
Entera Bio beats Atara Biotherapeutics on 10 of the 17 factors compared between the two stocks.
Get Entera Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for ENTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ENTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Entera Bio Competitors List
Related Companies and Tools
